1-(6-氯-2-吡嗪基)-4-甲基哌嗪 | 61655-77-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(6-氯-2-吡嗪基)-4-甲基哌嗪
• 中文别名: 2-氯-6-(4-甲基哌嗪-1-基)吡嗪
• 英文名称: 2-chloro-6-(4-methylpiperazin-1-yl)pyrazine
• CAS: 61655-77-4
• 化学式: C₉H₁₃ClN₄
• 分子量: 212.682
• InChiKey: ZMVHGTJAFGHEBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P305+P351+P338,P280
• 危险性描述：
  H319,H317

反应信息

• 作为反应物：
  描述：

  1-(6-氯-2-吡嗪基)-4-甲基哌嗪 在 nitronium tetrafluoborate 作用下， 以 乙腈 为溶剂， 反应 0.5h， 以8%的产率得到6'-chloro-4-methyl-5'-nitro-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl
  参考文献：
  名称：

  WO2006/47504

  摘要：

  公开号：
• 作为产物：
  描述：

  N-甲基哌嗪 、 2,6-二氯吡嗪 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.33h， 以91%的产率得到1-(6-氯-2-吡嗪基)-4-甲基哌嗪
  参考文献：
  名称：

  1,3,4-恶二唑-2（3H）-硫酮类似物作为PIM激酶抑制剂

  摘要：

  莫洛尼鼠白血病病毒（PIM）激酶的前病毒整合位点在血液系统癌症中高度表达。它们磷酸化有助于肿瘤生长和存活的下游底物。因此，预期PIM激酶的有效抑制剂可有效治疗血液学癌症。在本研究中，合成了1,3,4-恶二唑-2（3 H）-硫酮的几种吲哚衍生物，并将其评估为PIM激酶抑制剂。结构-活性关系研究得出了所有三种PIM激酶的有效抑制剂，其单位数至低两位数纳摩尔级IC 50范围内。代表性化合物的激酶图谱显示了在其他15种激酶中的高选择性。

  DOI：

  10.1002/bkcs.12101

文献信息

• THERAPEUTIC COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20130281433A1

  公开（公告）日：2013-10-24

  Compounds disclosed herein including compounds of formula I′: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.

  本文披露的化合物包括公式I′的化合物及其盐。还提供了包含本文披露的化合物的药物组合物、制备本文披露的化合物的方法、用于制备本文披露的化合物的中间体以及使用本文披露的化合物治疗HIV感染的治疗方法。
• Synthesis and Evaluation of 5-(3-(Pyrazin-2-yl)benzylidene)thiazolidine-2,4-dione Derivatives as Pan–Pim Kinases Inhibitors
  作者：Jinho Lee、Jongseong Park、Victor Sukbong Hong

  DOI：10.1248/cpb.c14-00325

  日期：——

  Pim kinases play a key role in the regulation of signaling pathways including proliferation, migration, and metabolism and are a potential target for cancer therapy. A series of 5-benzylidenethiazolidine-2,4-diones were synthesized as pim kinase inhibitors. The structure–activity relationships (SAR) of the analogues in inhibiting in vitro pim kinase activity as well as the proliferation of leukemia cell lines were examined. SAR studies indicated that a hydroxyl group at the 2-position of the benzene ring of 5-benzylidenethiazolidine-2,4-dione plays an important role in the inhibitory activity against all three pim kinases and replacement with a pyrazinyl group at the 5-position of the benzene ring of 5-benzylidenethiazolidine-2,4-dione improved activity significantly. The compounds exerted anti-proliferative activity against the three leukemia cell lines we tested. The most potent compound, 5i, had an EC50 value of 0.8 µM in the MV4-11 cell line. The result of kinase profiling indicated that compound 5i was highly selective for pim-kinases.

  Pim激酶在调控包括增殖、迁移和代谢等信号通路中发挥关键作用，并且是癌症治疗的潜在靶点。一系列5-苄叉噻唑烷-2,4-二酮被合成作为pim激酶抑制剂。研究了这些类似物在体外抑制pim激酶活性和白血病细胞系增殖的结构-活性关系（SAR）。SAR研究表明，5-苄叉噻唑烷-2,4-二酮的苯环2位上的羟基在抑制所有三种pim激酶的活性中起重要作用，而将5-苄叉噻唑烷-2,4-二酮的苯环5位上的取代基替换为吡嗪基团可显著提高活性。这些化合物对我们在测试的三种白血病细胞系展现出抗增殖活性。最强的化合物5i在MV4-11细胞系中的EC50值为0.8µM。激酶谱分析结果表明，化合物5i对pim激酶具有高度选择性。
• Inhibitors of c-fms kinase
  申请人：Illig R. Carl

  公开号：US20060100201A1

  公开（公告）日：2006-05-11

  The invention relates to compounds of Formula I: wherein A, X, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及公式I的化合物：其中A、X、R2和W在说明书中设置，以及其溶剂化物、水合物、互变异构体和药学上可接受的盐，它们抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了利用公式I的化合物治疗自身免疫性疾病和具有炎症成分的疾病；治疗卵巢癌、子宫癌、乳腺癌、结肠癌、胃癌、毛细胞白血病和非小细胞肺癌的转移；以及治疗疼痛，包括肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经性疼痛；以及骨质疏松症、Paget病和其他骨吸收介导的疾病，包括关节炎、假体失效、骨溶性肉瘤、骨髓瘤和肿瘤转移至骨骼。
• Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
  申请人：——

  公开号：US20040092508A1

  公开（公告）日：2004-05-13

  This invention relates to use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as to pharmaceutical compositions comprising these substances and chemical substances for use according to the invention.

  本发明涉及使用尼古丁型乙酰胆碱受体激动剂和单胺类物质的联合作用治疗情感障碍，以及包含这些物质的制药组合物和用于本发明的化学物质。
• TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE
  申请人：Olsen M. Gunnar

  公开号：US20070265241A1

  公开（公告）日：2007-11-15

  This invention relates to use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as to pharmaceutical compositions comprising these substances and chemical substances for use according to the invention.

  本发明涉及使用尼古丁型乙酰胆碱受体激动剂和单胺类物质的联合作用治疗情感障碍，以及包含这些物质的药物组合物和用于本发明的化学物质。